SEC Filing Summary: PharmAthene, Inc. (Form 8-K)
Business Context and Reporting Period
This Form 8-K was filed by PharmAthene, Inc. on February 19, 2016, reporting an event that occurred on February 15, 2016. The registrant is a Delaware corporation headquartered in Annapolis, Maryland. Note: The request metadata references "Altimmune, Inc.," but the filing text explicitly identifies the registrant as "PharmAthene, Inc."
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on a specific executive compensation event.
Material Changes
The Board of Directors approved a one-time cash bonus of $125,000 for John Gill, the Company's President and Chief Executive Officer. This award was based on the Compensation Committee's conclusion that Mr. Gill satisfied 100% of his performance objectives for the 2015 fiscal year.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, risk factors, contingencies, or unusual items beyond the executive compensation award.
Investor Verification Checklist
- Verify the exact amount of the bonus awarded to the CEO ($125,000).
- Confirm the performance period covered by the bonus (2015).
- Review the Company's 2015 Annual Report (Form 10-K) for details on the specific performance objectives met.
- Check subsequent filings for the actual payment date and accounting treatment of this bonus.